Benjamin Chastek - Concepedia

Author

Benjamin Chastek

Optum (United States)ORCID

Also Known As

B Chastek, B. Chastek, B.J. Chastek, Benjamin Chastek, Benjamin J Chastek, Benjamin J. Chastek, Chastek Benjamin

121

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Optum (United States)Amgen (United States)University of Alabama at Birmingham Sanofi (United States)GlaxoSmithKline (United States)

About

Benjamin Chastek is an author at Optum (United States).

Benjamin Chastek

Publications

Citations

H-Index

Page 1

	Year	Citations
Health Care Costs for Patients With Cancer at the End of Life Benjamin Chastek, Carolyn Harley, Joel Kallich, Journal of Oncology Practice	2012	253
Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting Benjamin Chastek, Stephanie Korrer, Saurabh Nagar, Journal of Managed Care & Specialty Pharmacy	2016	123
Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims Benjamin Chastek, MerriKay Oleen-Burkey, Maria Lopez-Bresnahan Journal of Medical Economics	2010	100
Estimating the Incidence and Prevalence of Juvenile-Onset Recurrent Respiratory Papillomatosis in Publicly and Privately Insured Claims Databases in the United States Mark Marsico, Vinay Mehta, Benjamin Chastek, Sexually Transmitted Diseases	2014	62
Racial and ethnic disparity in clinical outcomes among patients with confirmed COVID-19 infection in a large US electronic health record database Ami Buikema, Paul Buzinec, Misti L. Paudel, EClinicalMedicine	2021	50
Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017 E. Michael Lewiecki, Benjamin Chastek, K. Sundquist, Osteoporosis International	2020	49
Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database Jessica A. Walsh, Oluwakayode Adejoro, Benjamin Chastek, Journal of Managed Care & Specialty Pharmacy	2018	44
A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients Benjamin Chastek, John White, Damon Van Voorhis, Advances in Therapy	2016	39
Cost and Effectiveness of Biologics for Rheumatoid Arthritis in a Commercially Insured Population Jeffrey R. Curtis, Benjamin Chastek, Laura Becker, Journal of Managed Care & Specialty Pharmacy	2015	36
Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis Benjamin Chastek, Laura Becker, Chieh-I Chen, Journal of Medical Economics	2016	35

Page 1